Avalo Therapeutics CFO Executes Stock Transactions via 10b5-1 Plan
Christopher Ryan Sullivan, the Chief Financial Officer of Avalo Therapeutics, Inc. (NASDAQ: AVTX), has completed a series of transactions involving the company's common stock. According to a Form 4 filing submitted to the Securities and Exchange Commission on May 11, 2026, these movements were conducted under a Rule 10b5-1 trading plan that Sulliva…